Presented by CTI Invest on 07.09.2011
ProteoMediX enables personalized medicine by developing non-invasive diagnostic tests to: detect the disease early, assess its prognosis accurately and to match patients with more effective therapies. The first products are focusing on prostate cancer, the most frequently diagnosed cancer in men and the second leading cause of male cancer-related deaths. Neither the detection nor the development of new improved drugs for prostate cancer is currently guaranteed.
Coach: Marcos Garcia Pedraza
| Founded |
2010 |
| Industry |
Biotech & Life Sciences
|
| Status |
no financial need for the moment |